Deciphera Pharmaceuticals, Inc.: Deciphera Announces Approval of QINLOCK in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Seventh Approval Worldwide for QINLOCK and First European Approval - Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines

Related Keywords

Switzerland ,China ,Australia ,Taiwan ,United States ,Canada ,Hong Kong ,Swiss ,Jen Robinson ,David Rosen ,Steve Hoerter ,Deciphera Announces Australian Therapeutic Goods Administration Approval ,Linkedin ,Deciphera Pharmaceuticals ,Deciphera Pharmaceuticals Inc ,Nasdaq ,European Union ,Committee For Medicinal Products Human Use ,Swiss Agency For Therapeutic Products Swissmedic ,Deciphera Announces Health Canada Authorization ,European Commission ,Exchange Commission ,Deciphera Press ,Zai Lab Press ,European Medicines Agency ,Clinical Cancer Research ,Seventh Approval Worldwide ,First European Approval ,Swiss Agency ,Therapeutic Products ,Chief Executive Officer ,Medicinal Products ,Human Use ,Private Securities Litigation Reform Act ,Quarterly Report ,Cancer Research ,Press Release ,Fourth Line Gastrointestinal Stromal Tumor ,Deciphera Announces Health Canada ,Lab Press Release ,Advanced Gastrointestinal Stromal Tumors ,Full Approval ,Deciphera Pharmaceutical ,Deciphera ,Pharmaceuticals ,Nnounces ,Approval ,Qinlock ,Treatment ,Fourth ,Line ,Gastrointestinal ,Tromal ,Humor ,